|
| CD74 negative | CD74 positive | p | HLA-DR negative | HLA-DR positive | p | |
| Group | Group | Group | Group | ||||
| Tumor stage |
|
| 0.9 |
|
| 0.5 | |
| T1 | 4 (21%) | 6 (27%) |
| 5 (22%) | 5 (28%) |
| |
| T2 | 12 (63%) | 13 (59%) |
| 13 (56%) | 12 (67%) |
| |
| T3 | 2 (11%) | 2 (9%) |
| 3 (13%) | 1 (5%) |
| |
| T4 | 1 (5%) | 1 (5%) |
| 2 (9%) | 0 |
| |
| Axillary lymph |
|
|
|
|
|
| |
| Node metastasis |
|
| 0.2 |
|
| 0.4 | |
| Positive | 10 (53%) | 16 (73%) |
| 16 (70%) | 10 (56%) |
| |
| Negative | 9 (47%) | 6 (27%) |
| 7 (30%) | 8 (44%) |
| |
| Nuclear grade |
|
| 0.3 |
|
| 0.2 | |
| Grade 1 | 5 (26%) | 6 (27%) |
| 8 (35%) | 3 (17%) |
| |
| Grade 2 | 11 (58%) | 16 (73%) |
| 12 (52%) | 15 (83%) |
| |
| Grade 3 | 3 (16%) | 0 |
| 3 (13%) | 0 |
| |
| Histological grade |
|
| 0.4 |
|
| 0.5 | |
| Grade 1 | 2 (11%) | 0 |
| 0 | 1 (6%) |
| |
| Grade 2 | 12 (63%) | 17 (77%) |
| 16 (70%) | 13 (72%) |
| |
| Grade 3 | 5 (26%) | 5 (23%) |
| 7 (30%) | 4 (22%) |
| |
| Distant metastasis |
| 0.8 |
|
| 0.6 | ||
| Positive | 8 (42%) | 10 (45%) |
| 10 (43%) | 8 (44%) |
| |
| Negative | 11 (58%) | 12 (55%) |
| 13 (57%) | 10 (56%) |
| |